NCT06140732View on ClinicalTrials.gov

Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

January 1, 2025

Study Completion Date

January 31, 2026

Conditions
ChordomaChemotherapy Effect
Interventions
DRUG

camrelizumab and apatinib

camrelizumab 200 mg iv/ q2w+ apatinib 375mg oral qd

Trial Locations (1)

Unknown

RECRUITING

BEIJING, Beijing

All Listed Sponsors
lead

Xuanwu Hospital, Beijing

OTHER